CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moves Closer to IND Filing as Manufacturing of Lead Drug Candidate Commences
Berubicin Expected to Commence Trials for the Treatment of Glioblastoma, An Aggressive Form of Brain Cancer Currently Considered IncurableProduction of Berubicin Begins in the U.S. and EuropeDual Manufacturing Facilities Engaged to Reduce Supply Chain InterruptionsIND for Berubicin Could Be Filed by Year End CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) expects to have an Investigational New Drug Application (“IND”) ready for its lead drug candidate, Berubicin, by…